English

• 

• 1. [1] G.M. Cragg, P.G. Grothaus, D.J. Newman, Impact of natural products on developing new anti-cancer agents, Chem. Rev. 109 (2009) 3012-3043.[1] G.M. Cragg, P.G. Grothaus, D.J. Newman, Impact of natural products on developing new anti-cancer agents, Chem. Rev. 109 (2009) 3012-3043.

  2. [2] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the 30 years from 1981 to 2010, J. Nat. Prod. 75 (2012) 311-335.[2] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the 30 years from 1981 to 2010, J. Nat. Prod. 75 (2012) 311-335.

  3. [3] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the last 25 years, J. Nat. Prod. 70 (2007) 461-477.[3] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the last 25 years, J. Nat. Prod. 70 (2007) 461-477.

  4. [4] N.H. Oberlies, D.J. Kroll, Camptothecin and taxol: historic achievements in natural products research, J. Nat. Prod. 67 (2004) 129-135.[4] N.H. Oberlies, D.J. Kroll, Camptothecin and taxol: historic achievements in natural products research, J. Nat. Prod. 67 (2004) 129-135.

  5. [5] J. Jiang, C. Hu, Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa, Molecules 14 (2009) 1852-1859.[5] J. Jiang, C. Hu, Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa, Molecules 14 (2009) 1852-1859.

  6. [6] Z.G. Yang, A.Q. Chen, B. Liu, Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205), Chem. Biodivers. 6 (2009) 924-933.[6] Z.G. Yang, A.Q. Chen, B. Liu, Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205), Chem. Biodivers. 6 (2009) 924-933.

  7. [7] G. Dong, C. Sheng, S. Wang, et al., Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents, J. Med. Chem. 53 (2010) 7521-7531.[7] G. Dong, C. Sheng, S. Wang, et al., Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents, J. Med. Chem. 53 (2010) 7521-7531.

  8. [8] G. Dong, S. Wang, Z. Miao, et al., New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations, J. Med. Chem. 55 (2012) 7593-7613.[8] G. Dong, S. Wang, Z. Miao, et al., New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations, J. Med. Chem. 55 (2012) 7593-7613.

  9. [9] H. Huang, Q. Chen, X. Ku, et al., A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIa catalytic activity, J. Med. Chem. 53 (2010) 3048-3064.[9] H. Huang, Q. Chen, X. Ku, et al., A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIa catalytic activity, J. Med. Chem. 53 (2010) 3048-3064.

  10. [10] L. Du, H.C. Liu, W. Fu, et al., Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIa inhibitor, J. Med. Chem. 54 (2011) 5796-5810.[10] L. Du, H.C. Liu, W. Fu, et al., Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIa inhibitor, J. Med. Chem. 54 (2011) 5796-5810.

  11. [11] G. Jones, P. Willett, R.C. Glen, et al., Development and validation of a genetic algorithm for flexible docking, J. Mol. Biol. 267 (1997) 727-748.[11] G. Jones, P. Willett, R.C. Glen, et al., Development and validation of a genetic algorithm for flexible docking, J. Mol. Biol. 267 (1997) 727-748.

  12. [12] B.L. Staker, M.D. Feese, M. Cushman, et al., Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex, J. Med. Chem. 48 (2005) 2336-2345.[12] B.L. Staker, M.D. Feese, M. Cushman, et al., Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex, J. Med. Chem. 48 (2005) 2336-2345.

  13. [13] H. Wei, A.J. Ruthenburg, S.K. Bechis, G.L. Verdine, Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase, J. Biol. Chem. 280 (2005) 37041-37047.[13] H. Wei, A.J. Ruthenburg, S.K. Bechis, G.L. Verdine, Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase, J. Biol. Chem. 280 (2005) 37041-37047.

  14. [14] Accelrys Software Inc., Discovery Studio Modeling Environment, Release 3.0, Accelrys Software Inc., San Diego, 2010.[14] Accelrys Software Inc., Discovery Studio Modeling Environment, Release 3.0, Accelrys Software Inc., San Diego, 2010.

  15. [15] K. Chikamori, A.G. Grozav, T. Kozuki, et al., DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy, Curr. Cancer Drug. Targets 10 (2010) 758-771.[15] K. Chikamori, A.G. Grozav, T. Kozuki, et al., DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy, Curr. Cancer Drug. Targets 10 (2010) 758-771.

  16. [16] A.T. Baviskar, C. Madaan, R. Preet, et al., N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIa and induce apoptosis in G1/S phase, J. Med. Chem. 54 (2011) 5013-5030.[16] A.T. Baviskar, C. Madaan, R. Preet, et al., N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIa and induce apoptosis in G1/S phase, J. Med. Chem. 54 (2011) 5013-5030.

•